

Resource Summary Report

Generated by RRID on Aug 6, 2026

c-erbB-2, c-neu

RRID:AB_10557104

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4290, RRID:AB_10557104

Antibody Information

URL: http://antibodyregistry.org/AB_10557104

Proper Citation: Cell Signaling Technology Cat# 4290, RRID:AB_10557104

Target Antigen: HER2/ErbB2 (D8F12) XP

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IHC-P. Consolidation on 11/2018: AB_10557104, AB_10828932. Info: Used By NYUIHC-1085.

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: c-erbB-2, c-neu

Description: This monoclonal targets HER2/ErbB2 (D8F12) XP

Antibody ID: AB_10557104

Vendor: Cell Signaling Technology

Catalog Number: 4290

Record Creation Time: 20250820T053734+0000

Record Last Update: 20250820T220254+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for c-erbB-2, c-neu.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

High PC, et al. (2025) Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models. bioRxiv : the preprint server for biology.

Lantz AE, et al. (2025) Creation and Characterization of a Breast Cancer Tissue Microarray Including Black and White Patients from Florida and Hispanic Patients from Puerto Rico and Florida. Cancer research communications, 5(5), 804.

High PC, et al. (2025) Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models. Cell reports. Medicine, 102363.

Trekitkarnmongkol W, et al. (2024) Epigenetic activation of SOX11 is associated with recurrence and progression of ductal carcinoma in situ to invasive breast cancer. British journal of cancer, 131(1), 171.

Zwirner S, et al. (2024) First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure. Cell, 187(7), 1666.

Huang P, et al. (2024) Peptostreptococcus stomatis promotes colonic tumorigenesis and receptor tyrosine kinase inhibitor resistance by activating ERBB2-MAPK. Cell host & microbe, 32(8), 1365.

Ji H, et al. (2024) The impact of quercetin and paclitaxel combination on ovarian cancer cells. iScience, 27(8), 110434.

Trenker R, et al. (2024) Structural dynamics of the active HER4 and HER2/HER4 complexes is finely tuned by different growth factors and glycosylation. eLife, 12.

Marrocco I, et al. (2023) L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab. Cell reports. Medicine, 4(8), 101142.

McKernan CM, et al. (2022) ABL kinases regulate translation in HER2+ cells through Y-box-binding protein 1 to facilitate colonization of the brain. *Cell reports*, 40(9), 111268.

Whiteaker JR, et al. (2021) Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling. *Cell reports methods*, 1(3).

Sun HL, et al. (2020) Stabilization of ERK-Phosphorylated METTL3 by USP5 Increases m6A Methylation. *Molecular cell*, 80(4), 633.

Al-Zeheimi N, et al. (2020) Modeling Neoadjuvant chemotherapy resistance in vitro increased NRP-1 and HER2 expression and converted MCF7 breast cancer subtype. *British journal of pharmacology*, 177(9), 2024.

Lukey MJ, et al. (2019) Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer. *Cell reports*, 29(1), 76.

Vaseva AV, et al. (2018) KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. *Cancer cell*, 34(5), 807.

Freed DM, et al. (2017) EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics. *Cell*, 171(3), 683.